Table 1.

Tumour antigens with potential for clinical application, including the antibody targets described in the manuscript, the technology used to identify these antibodies and (pre)clinical evaluation

Antigen	Antibody identification	Clinical evaluation	References
Targets of allogeneic B-cell responses
BCMA	cDNA serum screen of patients with MM after allogeneic HCT and DLI	Antibody–drug conjugate, CAR-T cells	35,36,63, 64, 65
CML28 CML66	cDNA serum screen of patients with CML after allogeneic HCT and DLI		7,20,21,85
RAFTK (PTK2B)	cDNA serum screen of patients with CML after allogeneic HCT and DLI and western blot analysis of serum specifically for PTK2B		7,37
NuSAP1	Protein array serum screen of patients with AML		26
snRNP200	Screening of immortalized donor-derived memory B cells after allogeneic HCT for AML	Tested in mouse models	33
CD43s	Screening of immortalized donor-derived memory B cells after allogeneic HCT for AML	Tested in mouse models	34,61,68
Targets of autologous B-cell responses relevant for haematologic malignancies
CD9	Screening of immortalized patient-derived memory B cells after adoptive T-cell transfer of tumour-reactive T cells for melanoma	Preclinical evaluation	82, 83, 84,86, 87, 88, 89
MUC1	Identified in serum of patients with many different types of tumours	Vaccine, CAR-T cells	69, 70, 71, 72, 73, 74NCT04020575

AML, acute myeloid leukaemia; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; CML, chronic myeloid leukaemia; DLI, donor lymphocyte infusion; HCT, haematopoietic cell transplantation; MM, multiple myeloma; MUC1, mucin 1; NuSAP1, nuclear and spindle-associated protein 1; RAFTK, related adhesion focal tyrosine kinase.